**Diagnostic and Therapeutic Challenges in Nonparasitic Liver Cysts**

Mirela Patricia Sîrbu Boeți, Mirela Boroș, Vlad Herlea, Amalia Petrișor and Irinel Popescu

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/61057

#### **Abstract**

[106] Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: An adjuvant to in‐ crease the cure rate of radiofrequency ablation in liver cancer. Future Oncol.

[107] Hossann M, Syunyaeva Z, Schmidt R, Zengerle A, Eibl H, Issels RD, Linder, LH. Pro‐ teins and cholesterol lipid vesicles are mediators of drug release from thermosensi‐

[108] Mills J.K, Needham D. Lysolipid incorporation in dipalmitoylphosphati-dylcholine bilayer membranes enhances the ion permeability and drug release rates at the mem‐

[109] Park K. Lessons learned from thermosensitive liposomes from improved chemother‐

[110] Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, et al.. Development of anti-p185HER2 immunoliposomes for cancer

[111] Kullberg M, Mann K, Owens JL. A two component drug delivery system using Her-2-targeting thermosensitive liposomes. J Drug Target. 2009;17(2):98-107.

[112] ] Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Con‐

[113] Dicheva BM, ten Hagen TL, Li L, Schipper D, Seynhaeve AL, van Rhoon GC, Egger‐ mont AM, Lindner LH, Koning GA. Cationic thermosensitive liposomes: aA novel dual targeted heat-triggered drug delivery approach for endothelial and tumor Cells.

tive liposomes. J Control. Release 2012:162;400-406.

apy. J Control.Release 2014;174:219.

trol. Release 2010;143(2): 265-273.

Nano Lett. 2013;13(6):2324-2331.

brane phase transition. Biochim Biophys Acta. 2005:1716;77-96.

therapy. Proc Natl Acad Sci USA. 1995;92(5):1327-1331.

2011;7(8):937-945.

248 Recent Advances in Liver Diseases and Surgery

Nonparasitic hepatic cysts constitute a heterogeneous group of disorders. A proper diagnosis of hepatic cyst is necessary in order to adopt the best treatment. The term hepatic cyst usually refers to simple hepatic cysts. Nonparasitic hepatic cysts are also linked to genetic disorders such as polycystic liver disease (PLD) with/ without autosomal dominant polycystic kidney disease (ADPKD) or Caroli disease. Generally, patients with nonparasitic hepatic cysts less than 3 cm are asymptomat‐ ic. These cysts become symptomatic when are large, multiple, or complicated. Percutaneous abdominal ultrasound is the best imaging modality to diagnose hepatic cysts but must be completed by other imaging and serological tests. It is important to differentiate simple hepatic cyst from hydatid cyst, cystadenoma, and cystadenocarcinoma before proceeding with the treatment. Sometimes the diagnosis is very challenging. Asymptomatic single liver cysts need only surveil‐ lance, but symptomatic and complicated ones require therapeutic intervention. Percutaneous aspiration of the cyst under ultrasound guidance is a mini-invasive procedure generally associated with sclerotherapy. The highest success rates were reported for laparoscopic or open cyst fenestration. Liver transplantation is indicated for patients with severe PLD.

**Keywords:** Simple hepatic cyst, serous hepatic cyst, nonparasitic hepatic cyst, poly‐ cystic liver disease

© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
